• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Warby Parker Inc. filed SEC Form 8-K: Regulation FD Disclosure

    12/8/25 1:13:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    false 0001504776 0001504776 2025-12-08 2025-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 8, 2025

     

    Warby Parker Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction

    of Incorporation)

    001-40825

    (Commission

    File Number)

    80-0423634

    (IRS Employer

    Identification No.)

     

    233 Spring Street, 6th Floor East

    New York, New York

    10013

    (Address of Principal Executive Offices) (Zip Code)

     

    (646) 847-7215

    (Registrant's Telephone Number, Including Area Code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

      Name of each exchange on which
    registered
    Class A Common Stock, $0.0001 par value   WRBY   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (P30.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 7.01.Regulation FD Disclosure

     

    As part of today’s The Android Show | XR Edition, Warby Parker Inc. (the “Company”) and Google announced that the first lightweight, AI glasses developed through their partnership are expected to launch in 2026.

     

    The information in this Item 7.01 is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    The disclosure under this Item 7.01 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These statements may relate to, but are not limited to, expectations regarding the development of new products, and management’s plans, priorities, initiatives and strategies. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “toward,” “will,” or “would,” or the negative of these words or other similar terms or expressions. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all. Information regarding risks and uncertainties that could cause actual results to differ materially from the Company's expectations is included in our most recent reports filed with the SEC on Form 10-K and Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      WARBY PARKER INC.
       
    Dated: December 8, 2025 By: /s/ Chris Utecht
        Chris Utecht
        General Counsel and Secretary

     

     

     

    Get the next $WRBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    12/10/2025$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    11/7/2025$28.00 → $24.00Outperform
    Telsey Advisory Group
    8/1/2025$22.00 → $28.00Outperform
    Telsey Advisory Group
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    More analyst ratings

    $WRBY
    SEC Filings

    View All

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    12/11/25 4:06:32 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Warby Parker Inc. (0001504776) (Filer)

    12/8/25 1:13:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Warby Parker Inc.

    SCHEDULE 13G/A - Warby Parker Inc. (0001504776) (Subject)

    12/5/25 2:03:43 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

    Warby Parker Inc. (NYSE: WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-

    11/26/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    8/14/24 4:52:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Warby Parker upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Warby Parker from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    12/10/25 9:45:30 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $24.00 from $28.00 previously

    11/7/25 7:48:31 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $28.00 from $22.00 previously

    8/1/25 8:16:04 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Gilboa David Abraham converted options into 9,816 shares and covered exercise/tax liability with 5,430 shares, increasing direct ownership by 13% to 37,247 units (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    12/4/25 5:03:08 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Blumenthal Neil Harris converted options into 9,816 shares and covered exercise/tax liability with 5,430 shares, increasing direct ownership by 13% to 37,119 units (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    12/4/25 5:02:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Gilboa David Abraham converted options into 125,000 shares and sold $3,412,500 worth of shares (125,000 units at $27.30) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    10/3/25 5:50:14 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    View All

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

    8/1/24 4:15:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Financials

    Live finance-specific insights

    View All

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Second Quarter 2025 Results

    Net revenue increased 14% year over year to $214 million; Raises outlook Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the second quarter ended June 30, 2025. "It has been a busy and exciting year marked by major milestones. We celebrated opening our 300th store and distributing 20 million pairs of glasses to people in need around the world. Looking ahead, our partnership with Google to develop intelligent eyewear is a testament to Warby Parker's commitment to innovation as we shape the future of how people

    8/7/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 5:08:23 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/12/24 10:40:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care